Related Experiment Video
Updated: Jun 4, 2026

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood
Published on: January 9, 2018
NMDA receptor antibody encephalitis
Sarosh R Irani1, Angela Vincent
1Nuffield Department of Clinical Neurosciences, Level 6, West Wing, John Radcliffe Hospital, Headley Way, Oxford OX39DS, UK. saroshirani@doctors.net.uk
Abstract:
N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is a recently described immunotherapy-responsive panencephalitis with characteristic features that include a psychiatric onset and a later movement disorder. This entity was first described as a paraneoplastic phenomenon in young women with ovarian teratomata. However, more recently it has become clear that the majority of patients, particularly children, do not harbor a tumor and that males can also be affected. With the development of the NMDAR antibody assay, now available worldwide, a few patients with classical limbic encephalitis and early psychosis and epilepsy have also been found to harbor these antibodies. Early diagnosis followed by immunotherapies and tumor removal, when relevant, expedite recovery from the condition. Antibody levels correlate with the clinical severity of the disease in individual patients, and the antibodies have been shown to substantially reduce NMDA receptors on hippocampal neurons both in vitro and in vivo, supporting the likely direct pathogenicity of the NMDAR antibodies.
Insights
N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is an immunotherapy-responsive condition. Early diagnosis and treatment, including tumor removal if applicable, improve patient outcomes and recovery.
Area of Science:
- Neuroimmunology
- Neurology
- Immunology
Background:
- N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is a recently identified, treatable autoimmune disorder.
- Initially described as a paraneoplastic syndrome in young women with ovarian teratomas, it now affects a broader demographic, including children and males, often without an identifiable tumor.
- The condition presents with characteristic psychiatric symptoms followed by movement disorders.
Purpose of the Study:
- To summarize the current understanding of NMDAR antibody encephalitis.
- To highlight the importance of early diagnosis and immunotherapy.
- To discuss the pathogenic role of NMDAR antibodies.
Main Methods:
- Review of clinical features, diagnostic advancements, and treatment outcomes.
- Analysis of the correlation between antibody levels and disease severity.
- In vitro and in vivo studies demonstrating the effect of antibodies on NMDA receptors.
Main Results:
- The NMDAR antibody assay is now globally available, facilitating diagnosis.
- Antibody levels correlate with clinical severity, indicating direct pathogenicity.
- NMDAR antibodies reduce NMDA receptor density on hippocampal neurons.
Conclusions:
- Early diagnosis of NMDAR antibody encephalitis followed by prompt immunotherapy and tumor resection (if applicable) is crucial for recovery.
- NMDAR antibodies are directly pathogenic, causing a reduction in functional NMDA receptors.
- The spectrum of NMDAR antibody encephalitis extends beyond young women with teratomas, affecting diverse populations.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Related Concept Videos
Encephalitis ll: Pathophysiology
Encephalitis l: Introduction
Arboviral Encephalitis
Rabies
Antiepileptic Drugs: Glutamate Antagonists